Beta Bionics closes USD 172.5 million common stock offering at USD 17.25 a share
BBNX•Use of proceeds
Net proceeds are earmarked for general corporate purposes, including Mint commercialization, manufacturing expansion, R&D, clinical development, and product enhancements.
Offering closed and proceeds raised
Beta Bionics closed an underwritten public offering raising USD 172.5 million in gross proceeds, before fees and expenses.
The deal included 7,652,175 common shares priced at USD 17.25 and pre-funded warrants for 1,043,484 shares priced at USD 17.2499.
Underwriters exercised their option in full for 1,304,348 additional common shares.
